138 related articles for article (PubMed ID: 24243606)
1. Interactions of platinum and ruthenium coordination complexes with pancreatic phospholipase A(2) and phospholipids investigated by MALDI TOF mass spectrometry.
Kamčeva T; Radisavljević M; Vukićević I; Arnhold J; Petković M
Chem Biodivers; 2013 Nov; 10(11):1972-86. PubMed ID: 24243606
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of platinum and ruthenium bipyridyl complexes on porcine pancreatic phospholipase A2.
Kamčeva T; Flemmig J; Damnjanović B; Arnhold J; Mijatović A; Petković M
Metallomics; 2011 Oct; 3(10):1056-63. PubMed ID: 21909579
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of cisplatin and [Pt(dach)Cl2] on the activity of phospholipase A2.
Radisavljević M; Kamčeva T; Bugarčić ŽD; Petković M
J Enzyme Inhib Med Chem; 2013 Aug; 28(4):651-60. PubMed ID: 22424180
[TBL] [Abstract][Full Text] [Related]
4. Biological activity and binding properties of [Ru(II)(dcbpy)2Cl2] complex to bovine serum albumin, phospholipase A2 and glutathione.
Nešić M; Popović I; Leskovac A; Petković M
Biometals; 2016 Oct; 29(5):921-33. PubMed ID: 27515969
[TBL] [Abstract][Full Text] [Related]
5. Structures and binding studies of the complexes of phospholipase A2 with five inhibitors.
Shukla PK; Gautam L; Sinha M; Kaur P; Sharma S; Singh TP
Biochim Biophys Acta; 2015 Apr; 1854(4):269-77. PubMed ID: 25541253
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of N₄ donor macrocyclic Schiff base ligands and their Ru (II), Pd (II), Pt (II) metal complexes for biological studies and catalytic oxidation of didanosine in pharmaceuticals.
Ravi Krishna E; Muralidhar Reddy P; Sarangapani M; Hanmanthu G; Geeta B; Shoba Rani K; Ravinder V
Spectrochim Acta A Mol Biomol Spectrosc; 2012 Nov; 97():189-96. PubMed ID: 22750687
[TBL] [Abstract][Full Text] [Related]
7. Mass spectrometry and inflammation--MS methods to study oxidation and enzyme-induced changes of phospholipids.
Fuchs B
Anal Bioanal Chem; 2014 Feb; 406(5):1291-306. PubMed ID: 24363111
[TBL] [Abstract][Full Text] [Related]
8. MALDI-TOF MS to monitor the kinetics of phospholipase A2-digestion of oxidized phospholipids.
Schröter J; Süß R; Schiller J
Methods; 2016 Jul; 104():41-7. PubMed ID: 26721598
[TBL] [Abstract][Full Text] [Related]
9. MALDI-Q-TOF mass spectrometric determination of gold and platinum in tissues using their diethyldithiocarbamate chelate complexes.
Minakata K; Nozawa H; Yamagishi I; Gonmori K; Suzuki M; Hasegawa K; Wurita A; Watanabe K; Suzuki O
Anal Bioanal Chem; 2014 Feb; 406(5):1331-8. PubMed ID: 23455689
[TBL] [Abstract][Full Text] [Related]
10. Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A
Mouchlis VD; Morisseau C; Hammock BD; Li S; McCammon JA; Dennis EA
Bioorg Med Chem; 2016 Oct; 24(20):4801-4811. PubMed ID: 27320659
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in ruthenium and platinum based supramolecular coordination complexes for antitumor therapy.
Zhang X; Liu D; Lv F; Yu B; Shen Y; Cong H
Colloids Surf B Biointerfaces; 2019 Oct; 182():110373. PubMed ID: 31376689
[TBL] [Abstract][Full Text] [Related]
12. Structure-based grafting, mutation, and optimization of peptide inhibitors to fit in the active pocket of human secreted phospholipase A2: find new use of old Peptide agents with anti-inflammatory activity.
Zhan C; Li S; Zhong Q; Zhou D
Chem Biol Drug Des; 2015 Apr; 85(4):418-26. PubMed ID: 25187416
[TBL] [Abstract][Full Text] [Related]
13. Combining in silico and in vitro approaches to identification of potent inhibitor against phospholipase A2 (PLA2).
Chinnasamy S; Selvaraj G; Selvaraj C; Kaushik AC; Kaliamurthi S; Khan A; Singh SK; Wei DQ
Int J Biol Macromol; 2020 Feb; 144():53-66. PubMed ID: 31838071
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of tocopheryl succinate phospholipid conjugates and monitoring of phospholipase A₂ activity.
Pedersen PJ; Viart HM; Melander F; Andresen TL; Madsen R; Clausen MH
Bioorg Med Chem; 2012 Jul; 20(13):3972-8. PubMed ID: 22672983
[TBL] [Abstract][Full Text] [Related]
15. Novel ruthenium complex K2[Ru(dmgly)Cl4].2H2O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes.
Djinović V; Momcilović M; Grgurić-Sipka S; Trajković V; Mostarica Stojković M; Miljković D; Sabo T
J Inorg Biochem; 2004 Dec; 98(12):2168-73. PubMed ID: 15541507
[TBL] [Abstract][Full Text] [Related]
16. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
Lazarević T; Rilak A; Bugarčić ŽD
Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
[TBL] [Abstract][Full Text] [Related]
17. Insights into the mechanism of action and cellular targets of ruthenium complexes from NMR spectroscopy.
Giannini F; Paul LE; Furrer J
Chimia (Aarau); 2012; 66(10):775-80. PubMed ID: 23146264
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, Biomacromolecular Interactions, Photodynamic NO Releasing and Cellular Imaging of Two [RuCl(qn)(Lbpy)(NO)]X Complexes.
Song L; Bai H; Liu C; Gong W; Wang A; Wang L; Zhao Y; Zhao X; Wang H
Molecules; 2021 Apr; 26(9):. PubMed ID: 33925453
[TBL] [Abstract][Full Text] [Related]
19. Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy.
Yusoh NA; Ahmad H; Gill MR
ChemMedChem; 2020 Nov; 15(22):2121-2135. PubMed ID: 32812709
[TBL] [Abstract][Full Text] [Related]
20. Modeling studies on phospholipase A2-inhibitor complexes.
Nirmal N; Praba GO; Velmurugan D
Indian J Biochem Biophys; 2008 Aug; 45(4):256-62. PubMed ID: 18788476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
